Loading
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Regular session
$9.90
−$0.28 · -2.75%
Regular session · ET · Market data may be delayed.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Day range
Current $9.90
52-week range
Current $9.90
Regular session · ET · Market data may be delayed.
GoAI Score
Sell
Valuation
63
Undervalued
Sentiment
41
Mixed
Risk
78
High Risk
Momentum
21
Weakening
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
Gossamer Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary hypertension and pulmonary arterial hypertension in the United States. The company develops GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH. It has license agreements with Pulmokine, Inc. to develop and commercialize GB002 and related backup compounds. The company was formerly known as FSG, Bio, Inc. and changed its name to Gossamer Bio, Inc. in 2017. The company was incorporated in 2015 and is headquartered in San Diego, California.
Day range
Current $9.90
52-week range
Current $9.90
Profitability as a percentage of reported revenue.
Revenue
Operating income
Net income
| Metric (USD) | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 48.47M USD | 114.7M USD | — | — | — |
| Cost of goods sold | 1M USD | — | — | — | — |
| Gross profit | 47.47M USD | 114.7M USD | — | — | — |
| Research and development | 174.09M USD | 138.49M USD | 135.3M USD | 170.92M USD | 170.27M USD |
| Selling, general, and administrative | 37.63M USD | 36.13M USD | 38.46M USD | 47.61M USD | 45.78M USD |
| Operating expenses | 210.72M USD | 174.62M USD | 183.76M USD | 218.59M USD | 216.12M USD |
| Interest income | 1.97M USD | 1.78M USD | 2M USD | 1.58M USD | 761K USD |
| Interest expense | 10.99M USD | 11.52M USD | 13.51M USD | 13.88M USD | 19.44M USD |
| Depreciation and amortization | 1M USD | 4.15M USD | 4.39M USD | 4.43M USD | 5.17M USD |
| Operating income | −163.25M USD | −59.92M USD | −183.76M USD | −218.59M USD | −216.12M USD |
| Net income | −170.37M USD | −56.53M USD | −179.82M USD | −229.38M USD | −234M USD |
Company facts updated Oct 8, 2026.
Recent quarterly results
Recent quarterly results
Third-party consensus; not a GoAI recommendation.
Average target
$3.47
64.95% downside| Action | Effective date | Details | Record date | Payment date |
|---|---|---|---|---|
Stock split | Sep 11, 2026 | 1:80 | — | — |
Effective Sep 11, 2026
1:80
Funds reporting this stock among their holdings, ordered by reported position size.
Vanguard Morningstar Total Stock Market ETFVTI1.17M0.00%2.3T USD0.03%$379.45-0.41%
iShares Biotechnology ETFIBB432.12K0.00%10.4B USD0.44%$197.57-2.84%
Vanguard Extended Market ETFVXF381.36K0.00%95.4B USD0.05%$231.21-0.98%
Vanguard Health Care ETFVHT224.16K0.00%22B USD0.09%$309.19-1.94%
Invesco RAFI US 1500 Small-Mid ETFPRFZ135.77K0.01%2.68B USD0.36%$52.265-0.88%
Eventide Small Cap ETFESSC32.69K0.10%35M USD0.49%$28.3249-1.07%
Invesco Nasdaq Biotechnology ETFIBBQ4.69K0.00%109.17M USD0.19%$33.11-2.65%
ProShares Ultra Nasdaq BiotechnologyBIB2.19K0.00%90.28M USD1.19%$101.76-5.31%Vanguard Morningstar Total Stock Market ETFVTIiShares Biotechnology ETFIBBVanguard Extended Market ETFVXFVanguard Health Care ETFVHTInvesco RAFI US 1500 Small-Mid ETFPRFZEventide Small Cap ETFESSCInvesco Nasdaq Biotechnology ETFIBBQProShares Ultra Nasdaq BiotechnologyBIBAI-generated and delayed market data for informational and educational purposes only. Not investment advice.
